Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23163150 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| SCHEMBL3103654 | 0.83 | PREP (0.43) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| SCHEMBL13244922 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| SCHEMBL4701620 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| SCHEMBL7845558 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| SCHEMBL4700147 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2C19PREPNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4701828 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2CYP2C19PREPALDH1A1 | |
| Hydrochloric Acid SCHEMBL4700390 | 0.78 | ALDH1A1 (0.43) | SMN1; SMN2CYP2C19PREPALDH1A1 | |
| SCHEMBL27286630 | 0.78 | ALDH1A1 (0.45) | PREPALDH1A1 | |
| SCHEMBL7842024 | 0.77 | PREP (0.42) | SMN1; SMN2PREPNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | SMN1; SMN2 3575/4885CYP2C19 1451/4885PREP 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.